It was shown that cancer cells expressing mutant p53 secrete more IL-6 that their wild-type (wt) counterparts because wt-p53 inhibits the binding of NF-κB, C/EBP, and CREB TFs to the IL-6 gene promoter [242]. Here, NFKB1 is linked to cancer.